AZD1152 in Patients With Advanced Solid Malignancies-Study 1

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-05-31

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 2-hour infusion every week and every 2 weeks in patients with advanced solid malignancies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AZD1152 in Patients With Advanced Solid Malignancies-Study 3

NCT00497679

Solid Tumours

TERMINATED PHASE1

AZD1152 in Patients With Advanced Solid Malignancies

NCT00338182

Tumors

COMPLETED PHASE1

A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.

NCT02579226

Advanced Solid Tumours

COMPLETED PHASE1

Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

NCT01112397

Solid Malignancies

TERMINATED PHASE1

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

NCT02482311

Ovarian Cancer, TNBC, SCLC, Other Solid Tumours

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD1152

2-hour continuous intravenous infusion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histological or cytological confirmation of a solid, malignant tumour
* At least measurable or non measurable site of disease as defined by modified RECIST criteria.

Exclusion Criteria

* Participation in an investigational drug study within 30 days prior to entry or who have not recovered from the effects of an investigational study drug
* Treatment with radiotherapy/chemotherapy with 4 weeks of first dose
* Recent major surgery within 4 weeks prior to entry to the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No